These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 23776241)

  • 21. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
    Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD73: an emerging checkpoint for cancer immunotherapy.
    Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
    Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    Yang X; Pei S; Wang H; Jin Y; Yu F; Zhou B; Zhang H; Zhang D; Lin D
    BMC Cancer; 2017 Apr; 17(1):255. PubMed ID: 28399915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.
    Qiao Z; Li X; Kang N; Yang Y; Chen C; Wu T; Zhao M; Liu Y; Ji X
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30823477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
    Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
    J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
    Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knock-out of CD73 delays the onset of HR-negative breast cancer by reprogramming lipid metabolism and is associated with increased tumor mutational burden.
    Serafin PK; Popęda M; Bulak K; Zwara A; Galikowska-Bogut B; Przychodzka A; Mika A; Śledziński T; Stanisławowski M; Jendernalik K; Bolcewicz M; Laprus W; Stasiłojć G; Sądej R; Żaczek A; Kalinowski L; Koszałka P
    Mol Metab; 2024 Nov; 89():102035. PubMed ID: 39304062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
    Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
    Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
    Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
    Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
    J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD73 expression as a potential marker of good prognosis in breast carcinoma.
    Supernat A; Markiewicz A; Welnicka-Jaskiewicz M; Seroczynska B; Skokowski J; Sejda A; Szade J; Czapiewski P; Biernat W; Zaczek A
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):103-7. PubMed ID: 22553809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
    Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
    Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
    Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
    Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Host surface ectonucleotidase-CD73 and the opportunistic pathogen,
    Lee JS; Chowdhury N; Roberts JS; Yilmaz Ö
    Virulence; 2020 Dec; 11(1):414-429. PubMed ID: 32419582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
    Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
    Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD73-adenosine: a next-generation target in immuno-oncology.
    Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
    Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
    Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.